Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
PLX
#3115
Protalix BioTherapeutics, Inc. Common Stock
2.830
0
USD
+1.07%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+1.07%
Changement Mensuel
-3.08%
Evolution sur 6 mois
-3.08%
Changement Annuel
-3.08%
Clôture Précédente
2.800
0
Open
2.820
0
Bid
2.830
0
Ask
2.833
0
Low
2.789
0
High
2.845
0
Volume
288
Marchés
Actions des Marchés US
Soins de Santé
PLX
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
73.63 M
78.03 M
79.61 M
79.73 M
80.42 M
—
Valuation ratios
Enterprise value
47.7 M
126.94 M
184.34 M
100.11 M
164.89 M
576.27 M
Price to earnings ratio
-8.5
47
51.2
16.44
27.75
142.39
Price to sales ratio
1.68
2.85
3.26
1.84
2.82
10.78
Price to cash flow ratio
50.02
17.57
21
6.2
9.64
54.4
Price to book ratio
0.62
3.53
1.31
0.67
0.91
6.41
Enterprise value to EBITDA ratio
-6.31
-36.71
56.42
14.49
32.39
66.6
Profitability ratios
Return on assets %
-0.05
-0.01
0.05
-0
-0.03
0.01
Return on equity %
-0.1
-0.01
0.08
-0
-0.04
0.02
Return on invested capital %
-62.76
1.73
39.94
-15.1
-15.89
10.67
Gross margin %
53.37
78.67
19.11
62.51
53.37
213.66
Operating margin %
-22.22
3.43
40.99
-7.48
-11.94
24.99
EBITDA margin %
24.05
41.4
-64.16
9.78
14.02
1.05
Net margin %
-18.02
-3.46
35.79
-1.05
-13.19
18.09
Liquidity ratios
Quick ratio
1.27
1.52
1.69
1.84
2.06
7.1
Current ratio
1.98
2.34
2.49
2.72
3.03
10.58
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.23
0.27
0.14
0.21
0.22
0.83
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0
—
—
—
—
Long term debt to total equity ratio
—
0
—
—
—
—
Per share metrics
Operating cash flow per share
0.06
0.05
0.07
0.07
0.05
0.23
EBIT per share
0.05
0.09
-0.09
0.02
0.03
0.04
EBITDA per share
0.06
0.09
-0.08
0.02
0.03
0.06
Total debt per share
—
—
—
—
—
—
Cash per share
0.37
0.24
0.25
0.23
0.17
0.9
Net current asset value per share
0.65
0.74
0.79
0.84
0.85
3.22
Tangible book value per share
0.44
0.53
0.59
0.64
0.68
2.44
Working capital per share
0.32
0.43
0.47
0.53
0.57
2
Book value per share
0.44
0.53
0.59
0.64
0.68
2.44
Protalix BioTherapeutics Inc (DE)
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Nouvelles
Brazil judge overrules decisions suspending changes to meal voucher system
A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)
Les actions de Pluxee et Edenred bondissent après des résultats et perspectives encourageants
Pluxee, Edenred shares jump after upbeat results and outlook
Présentation des résultats du T1 2026 de Pluxee : croissance de 9% malgré les défis brésiliens
Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds
Protalix présente sa stratégie pour 2026 axée sur le traitement de la goutte non contrôlée
Tuesday’s Insider Activity: Key Execs Make Notable Trades
Bashan Dror, PDG de Protalix BioTherapeutics, achète des actions pour 101k€
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)
Protalix and Secarna partner to develop rare kidney disease treatments
Pluxee révise ses perspectives pour l’exercice 2026 suite aux changements réglementaires au Brésil